ConductScience.org, home

Paper33014387

Introduction to immunotherapy for brain tumor patients: challenges and future perspectives.

Montoya ML and 2 others. Neurooncol Pract, 2020. Cited by 20 papers, by iCite.

Cite this record

ConductScience Library. Introduction to immunotherapy for brain tumor patients: challenges and future perspectives. Papers, record 33014387. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33014387

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Introduction to immunotherapy for brain tumor patients: challenges and future perspectives.
PubMed
Journal
Neurooncol Pract
PubMed
Year
2020
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
20
iCite
Relative citation ratio, by iCite
0.8
iCite
Revised in PubMed
2024-03-31
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Montoya MLMegan L
2Kasahara NNoriyuki
3Okada HHideho

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R01 CA222965NCI NIH HHSUnited StatesR01CA222965PubMedNIH RePORTER
R21 NS104454NINDS NIH HHSUnited StatesR21NS104454PubMedNIH RePORTER
R35 NS105068NINDS NIH HHSUnited StatesR35NS105068PubMedNIH RePORTER

Download CSV of grants

References95

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129244745Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity.Viruses2017https://conductscience.org/library/papers/29244745PubMed
231320597A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma.Clin Cancer Res2019https://conductscience.org/library/papers/31320597PubMed
322661320K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas.Acta Neuropathol2012https://conductscience.org/library/papers/22661320PubMed
431040917PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor models.Oncotarget2019https://conductscience.org/library/papers/31040917PubMed
528426845HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial.JAMA Oncol2017https://conductscience.org/library/papers/28426845PubMed
627314913
Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma.
Hum Gene Ther Clin Dev2016https://conductscience.org/library/papers/27314913PubMed
723462419Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.Int J Radiat Oncol Biol Phys2013https://conductscience.org/library/papers/23462419PubMed
826545842Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.Lancet Oncol2015https://conductscience.org/library/papers/26545842PubMed
920727764CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival.J Clin Neurosci2010https://conductscience.org/library/papers/20727764PubMed
1024764576Oncolytic viruses and their application to cancer immunotherapy.Cancer Immunol Res2014https://conductscience.org/library/papers/24764576PubMed
1127020328Corticosteroids compromise survival in glioblastoma.Brain2016https://conductscience.org/library/papers/27020328PubMed
1219116635Phase ib trial of oncolytic herpes virus G207 shows safety of multiple injections and documents viral replication.Mol Ther2009https://conductscience.org/library/papers/19116635PubMed
1324553386Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.Sci Transl Med2014https://conductscience.org/library/papers/24553386PubMed
1428029927Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.N Engl J Med2016https://conductscience.org/library/papers/28029927PubMed
1525517610Balance and imbalance in the immune system: life on the edge.Immunity2014https://conductscience.org/library/papers/25517610PubMed
1631646087Trial watch: dendritic cell vaccination for cancer immunotherapy.Oncoimmunology2019https://conductscience.org/library/papers/31646087PubMed
1727120786IDH-1R132H mutation status in diffuse glioma patients: implications for classification.Oncotarget2016https://conductscience.org/library/papers/27120786PubMed
1830568305Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial.Nature2019https://conductscience.org/library/papers/30568305PubMed
1924329793Design and development of therapies using chimeric antigen receptor-expressing T cells.Immunol Rev2014https://conductscience.org/library/papers/24329793PubMed
2029087782Vaccination in the immunotherapy of glioblastoma.Hum Vaccin Immunother2018https://conductscience.org/library/papers/29087782PubMed

See all 95 referencesDownload CSV of references

Cited by18

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.

PMIDTitleJournalYearIn PapersSource
42156731Non-lytic viral immunotherapy induces long-term glioblastoma survival and tumor-specific immunity without eliciting an antiviral response.Nat Commun2026https://conductscience.org/library/papers/42156731PubMed
41993610Translational Models for Glioblastoma: Revolutionizing Drug Development and Personalized Medicine through Clinical Insights.Theranostics2026https://conductscience.org/library/papers/41993610PubMed
41166287Identification of natural Zika virus peptides presented on the surface of paediatric brain tumour cells by HLA class I.PLoS One2025https://conductscience.org/library/papers/41166287PubMed
40507329Immunotherapy for High-Grade Gliomas.Cancers (Basel)2025https://conductscience.org/library/papers/40507329PubMed
40047938Prostaglandin F2 receptor negative regulator as a potential target for chimeric antigen receptor-T cell therapy for glioblastoma.Cancer Immunol Immunother2025https://conductscience.org/library/papers/40047938PubMed
39799339Personalising glioblastoma medicine: explant organoid applications, challenges and future perspectives.Acta Neuropathol Commun2025https://conductscience.org/library/papers/39799339PubMed
39669560
A comprehensive neuroimaging review of the primary and metastatic brain tumors treated with immunotherapy: current status, and the application of advanced imaging approaches and artificial intelligence.
Front Immunol2024https://conductscience.org/library/papers/39669560PubMed
37129737Assessment of treatment response to dendritic cell vaccine in patients with glioblastoma using a multiparametric MRI-based prediction model.J Neurooncol2023https://conductscience.org/library/papers/37129737PubMed
36601313Identification of glioblastoma-specific antigens expressed in patient-derived tumor cells as candidate targets for chimeric antigen receptor T cell therapy.Neurooncol Adv2023https://conductscience.org/library/papers/36601313PubMed
35990704The effect of dexamethasone on the microenvironment and efficacy of checkpoint inhibitors in glioblastoma: a systematic review.Neurooncol Adv2022https://conductscience.org/library/papers/35990704PubMed
34765977A randomized phase II trial of efficacy and safety of the immunotherapy ALECSAT as an adjunct to radiotherapy and temozolomide for newly diagnosed glioblastoma.Neurooncol Adv2021https://conductscience.org/library/papers/34765977PubMed
34539626Prognostic Gene Expression Signature in Patients With Distinct Glioma Grades.Front Immunol2021https://conductscience.org/library/papers/34539626PubMed
34466804Mouse models of glioblastoma for the evaluation of novel therapeutic strategies.Neurooncol Adv2021https://conductscience.org/library/papers/34466804PubMed
34321465MicroRNA-361-5p slows down gliomas development through regulating UBR5 to elevate ATMIN protein expression.Cell Death Dis2021https://conductscience.org/library/papers/34321465PubMed
34041027World Cancer Day 2021 - Perspectives in Pediatric and Adult Neuro-Oncology.Front Oncol2021https://conductscience.org/library/papers/34041027PubMed
33918043Physiological Imaging Methods for Evaluating Response to Immunotherapies in Glioblastomas.Int J Mol Sci2021https://conductscience.org/library/papers/33918043PubMed
33524947Using viral vectors to deliver local immunotherapy to glioblastoma.Neurosurg Focus2021https://conductscience.org/library/papers/33524947PubMed
33389564Immunologic aspects of viral therapy for glioblastoma and implications for interactions with immunotherapies.J Neurooncol2021https://conductscience.org/library/papers/33389564PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33014387

GET https://conductscience.org/api/papers/v1/33014387/references?page=2